6533b86cfe1ef96bd12c8c17

RESEARCH PRODUCT

Tumor cell specific toxicity of Inula helenium extracts.

David C. DornAugust DornJan G. HengstlerMaja Alexenizer

subject

Programmed cell deathCell SurvivalContext (language use)Plant RootsLethal Dose 50Cell Line TumorToxicity Tests AcuteHumansMTT assayLymphocytesAnnexin A5CytotoxicityPharmacologyInulabiologyMutagenicity TestsPlant Extractsbiology.organism_classificationMolecular biologyAntineoplastic Agents PhytogenicApoptosisCell cultureImmunologyInulaHT29 CellsHelenium

description

The aim of the research program was to identify botanical extracts with antineoplastic activity. In this respect extracts prepared from Inula helenium roots showed a remarkable activity. As evidenced by the MTT assay, the Inula helenium extract revealed a highly selective toxicity toward four different tumor cell lines (HT-29, MCF-7, Capan-2 and G1), but a much lower toxicity against healthy human peripheral blood lymphocytes (PBLs) from two donors. The extract-induced death of tumor cells was studied extensively by electron microscopy. There was a remarkable similarity of morphological alterations observed in the four cell lines: patchy chromatin condensations, cytoplasmic vesiculation, swelling and rupture of mitochondria. The morphology of cellular breakdown bore more resemblance to necrotic than to apoptotic cell death, which was supported by the failure to mark early apoptotic events by Annexin V. It has been pointed out recently that compounds inducing cell death with necrotic-like morphology could be very beneficial in cases where cancerous cells have gained resistance to apoptosis. In this context, the remarkable difference in cytotoxicity exerted by the Inula helenium extract, which was over 100-times higher in the tumor cell lines than in the PBLs, makes the extract an excellent candidate for further anticancerous investigations, especially since the Inula helenium extract was not mutagenic in the Ames test.

10.1002/ptr.1991https://pubmed.ncbi.nlm.nih.gov/16912983